Stock AnalizPennant Group, Inc. PNTG
Medical/Nursing Services · data as of November 13, 2026
Pennant Group, Inc. (PNTG) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to September 30, 2026 it had revenue of $1.2B and net income of $36M, a net margin of 3.1%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 36.1, a price to free cash flow of 36.9, 5-year revenue growth of 19% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.
Score: 2.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year average ROIC above 12%
- ROE above 15%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $948M | $695M | $545M | $473M | $440M | $391M | $339M | $286M | $251M |
| Net income | $36M | $30M | $23M | $13M | $7M | $3M | $16M | $3M | $16M | $10M |
| Free cash flow | $34M | $36M | $30M | $25M | -$5M | -$25M | $43M | $3M | $20M | $14M |
| EPS (diluted) | $1.00 | $0.84 | $0.70 | $0.44 | $0.22 | $0.09 | $0.52 | $0.11 | $0.58 | $0.36 |
| Net margin | 3.1% | 3.1% | 3.2% | 2.5% | 1.4% | 0.6% | 4.0% | 0.8% | 5.5% | 3.9% |
| ROIC | — | 4.7% | 5.1% | 3.8% | 2.3% | 0.8% | 3.9% | 0.8% | 24.9% | 16.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $48.00, 33% above the current price; targets range from $46.00 to $50.00; the consensus rating is “Strong buy”; expected EPS is $1.39 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Pennant Group’s P/E ratio?
About 36.1, based on the last twelve months of diluted earnings per share (forward P/E about 24.0).
Is Pennant Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Pennant Group pay a dividend?
Not currently.
Is Pennant Group a good stock to buy?
We do not give buy or sell advice. Pennant Group scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.